Reimbursement, Regulations Top List of Challenges Faced by PGx in 2005 | GenomeWeb

Developments in the field of pharmacogenomics gained significant traction in 2004. The release of pioneering technologies, regulatory approvals, and novel discoveries could hasten the discipline’s downstream move.

But for all the successes of 2004, it remains clear that pharmacogenomics still has significant barriers to overcome — reimbursement, physician education, regulatory guidance — before it becomes more widely available or applicable.

Here, Pharmacogenomics Reporter presents a few key events and actors worth watching in 2005.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.